Investigating how Cyclin E1 affects ovarian cancer and potential treatments
Official title: The Immunomodulatory Function of Cyclin E1 in Ovarian Cancer and Therapeutic Targeting
Funded at Roswell Park Cancer Institute Corp · NIH-11053623 · Data updated 2026-11-12
This study is looking at how a protein called Cyclin E1 affects high-grade serous ovarian cancer and how it might help us find better treatments for women with this type of cancer.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $505,851 |
| NIH project number | 5R37CA279440-02 |
| Project ID | NIH-11053623 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women diagnosed with high-grade serous ovarian cancer, particularly those with Cyclin E1 overexpression or amplification.
✕Less likely to help
Patients with other types of ovarian cancer or those without Cyclin E1 alterations may not benefit from this research.
What this research studies
This research focuses on understanding the role of Cyclin E1 in high-grade serous ovarian cancer (HGSOC), which is a leading cause of cancer-related deaths among women. The study will utilize patient-derived xenograft models to explore how Cyclin E1 influences tumor behavior and response to therapies. By examining the interactions between Cyclin E1 and the immune environment of the tumor, the research aims to identify new therapeutic strategies for patients with specific genetic profiles related to Cyclin E1 expression.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with high-grade serous ovarian cancer that currently have limited effective therapies.
How similar studies have gone: Previous research has shown promising results in targeting similar pathways in ovarian cancer, indicating potential for success in this novel approach.
Where this research is happening
-
Roswell Park Cancer Institute Corp
Buffalo, United States Active
Researchers
- Principal investigator: Ding, Liya — Roswell Park Cancer Institute Corp
- Study coordinator: Ding, Liya
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.